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Abstract
We analyze the patent filing strategies of foreign pharmaceutical companies in Chile distin-
guishing between “primary” (active ingredient) and “secondary” patents (patents on modi-
fied compounds, formulations, dosages, particular medical uses, etc.). There is prior
evidence that secondary patents are used by pharmaceutical originator companies in the U.
S. and Europe to extend patent protection on drugs in length and breadth. Using a novel
dataset that comprises all drugs registered in Chile between 1991 and 2010 as well as the
corresponding patents and trademarks, we find evidence that foreign originator companies
pursue similar strategies in Chile. We find a primary to secondary patents ratio of 1:4 at the
drug-level, which is comparable to the available evidence for Europe; most secondary pat-
ents are filed over several years following the original primary patent and after the protected
active ingredient has obtained market approval in Chile. This points toward effective patent
term extensions through secondary patents. Secondary patents dominate “older” therapeu-
tic classes like anti-ulcer and anti-depressants. In contrast, newer areas like anti-virals and
anti-neoplastics (anti-cancer) have a much larger share of primary patents.
Introduction
Historically, pharmaceutical patents are among the most controversially debated issues with re-
gard to intellectual property (IP) protection, especially in developing countries. During the ne-
gotiations of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement,
pharmaceutical product patents represented one of the most divisive issues, being opposed by
developing countries because of concerns that stronger patent protection would hinder access
to drugs and prevent the development of a domestic pharmaceutical industry. The TRIPS
agreement forced developing country members of the World Trade Organization (WTO) to
grant patents with a statutory lifetime of 20 years from the patent application also to pharma-
ceutical compounds. Almost two decades after TRIPS, the empirical evidence on its effect on
developing countries is at best mixed [1–3].
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Despite the strengthening of IP protection brought about by TRIPS, some developing coun-
tries continue to apply a more restrictive approach than developed countries to the granting of
pharmaceutical patents. While TRIPS requires the availability of patent protection for process-
es as well as products in “all fields of technology” (TRIPS Article 27.1), the agreement provides
countries with substantial freedom to define the standards of patentability. Some developing
countries, most prominently India (Section 3(d) of India’s Amended Patents Act of 2005),
have used this freedom to restrict the granting of so-called secondary pharmaceutical patents.
As opposed to primary patents which protect an active ingredient directly, secondary patents
protect a range of chemicals related to an active ingredient (such as crystalline forms of the
original compound), methods of use, formulations, dosages, etc. Other developing countries,
such as Brazil, Argentina and South Africa, are currently debating new legislation that would
emulate India’s approach to restricting the patentability of secondary patents.
In developing countries, secondary patents may have played particularly important a role
for multinational originator companies during the years following the introduction of pharma-
ceutical patents. When developing countries began to allow the granting of pharmaceutical
product patents, in many instances originator companies were unable to obtain patent protec-
tion for drugs that had already been patented abroad. In Chile, for example, pharmaceutical
patents were introduced in 1991, but pharmaceutical drugs that had been patented abroad be-
fore the 1991 law came into effect were expressly not patentable. This may have created strong
incentives for originator companies to rely on new secondary patents instead.
The sparse, available evidence on secondary patents, which focuses on the U.S. and the Eu-
ropean Union (EU) (see the next section), offers some evidence on the use of secondary patents
by originator companies. Empirical and anecdotal evidence suggests that pharmaceutical origi-
nator companies use secondary patents extensively in those markets. There is also some evi-
dence that secondary patents can be used to extend patent protection on a given drug in length
and breadth and it may create legal uncertainty over the scope of patent protection of a drug.
That said, secondary patents can be used to protect genuine follow-on innovation, although
distinguishing strategic use of secondary patents from their use to protect follow-on innovation
is very difficult and may not even be feasible when such patents serve both purposes.
Despite the widespread use of secondary patents and the contentious policy debate, there is
little evidence on the use of primary and secondary patents in developing countries. Our objec-
tive in this paper is to shed light on the use of primary and secondary patents by multinational
originator companies in Chile and to gauge their effect on creating and
maintaining exclusivity.
From a data point of view, studying this question is challenging because it requires not only
a distinction between primary and secondary patents, but also a mapping of patents to active
ingredients and the corresponding pharmaceutical products. Linking patents to active ingredi-
ents is an enormous challenge because there is usually no explicit mention in the patent claims
of the active ingredient contained by a drug (where drugs can contain multiple active ingredi-
ents). We create a new dataset that addresses this problem in three ways. First, we rely on the
Orange Book of the U.S. Food and Drug Administration (USFDA) to identify U.S. patents on
the compounds registered in Chile. We then construct patent families for these U.S. patents
and verify whether there are any Chilean equivalents. Similarly, we undertake the same exercise
using the Merck Index, which provides information on patents worldwide. Second, we use a
dataset created by the Chilean patent office (INAPI) that contains the compound-patent map-
ping for all new compounds registered in Chile between 2005 and 2010. All of these matches
are based on patent applications, whether granted or not. Third, we asked experts in pharma-
ceutical patents in Chile to match directly the remaining set of all granted Chilean patents to
the complete list of drugs registered with the Chilean health authorities. This means that we
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attempted to match all granted Chilean patents to drugs, either directly or through any of the
other approaches, although most of the patents do not match, as we show below. Unfortunate-
ly, for cost reasons, we were unable to search the remaining patent applications for matches to
registered drugs, but based on our earlier match rates, we expect there to be very few of these.
Because companies can obtain competitive advantage also through brand recognition, we
also match the pharmaceutical product-level data with trademark data. The mapping of drugs
and trademarks is more straightforward than that of drugs and patents. The pharmaceutical
product data provides the names under which drugs are marketed, which we search for in the
relevant classes in our trademark database.
For the matching of patents and trademarks, we rely on a dataset that contains the universe
of patent and trademark applications filed with the Chilean patent office (INAPI) between
1991 and 2010 [4]. The pharmaceutical product data comes from the National Public Health
institute (ISP). In Chile, all pharmaceutical products that are to be sold on the domestic market
have to be registered with the institute. It maintains a database that links all registered drugs in
Chile to the pharmaceutical compounds that they contain.
Our study contributes to the sparse empirical literature on the use of secondary patents, in
particular by foreign multinationals. It offers in particular for the first time empirical evidence
on the use of secondary patents in a developing country.
Primary and Secondary Patents
In the pharmaceutical industry, patents are usually filed already during the research phase in
the development of a new drug. These early patents are filed to protect potential active ingredi-
ents that form the basis of the new drug. Since the early stages of drug development are charac-
terized by an enormous amount of uncertainty (the European Commission [5] suggests that 1
in 5,000–10,000 test active ingredients results in a successful drug), early patent filings reflect
this, in that many of these filings will either not be pursued, or if granted, will never be related
to a marketed drug. Patents on active ingredients are referred to as primary patents. In later
phases of the drug development, patents are filed on other aspects of active ingredients such as
different dosage forms, formulations, production methods etc. These patents are referred to as
secondary patents. Secondary patents also emerge from changes to formulations and dosages
or applications in new therapeutic classes, discovered during clinical trials. [6] reports that the
usual filing strategy is to file many and broad primary patent applications and then to surround
them with secondary patent applications.
A critical issue regarding secondary patents is whether they protect genuine follow-on inno-
vation or whether they represent primarily a form of strategic patenting (although these two
may not necessarily be mutually exclusive). There is little controversy about the innovation as-
sociated with new active ingredients. However, new uses of existing active ingredients in new
therapeutic areas, new formulations, new modes of delivery, new combinations of known active
ingredients etc. are sometimes regarded as incremental innovation. In this case, secondary pat-
ents represent a way of incentivizing and protecting potentially valuable follow-on innovation.
This may be particularly valuable for generics producers that want to develop proprietary
drugs by modifying existing active ingredients as a lower risk strategy. For example, consider a
new formulation that allows administering an active ingredient in form of a temperature-stable
pill instead of a temperature-sensitive soft-gel version [7]. It is clear that the pill has no added
therapeutic benefit over the soft-gel version; at the same time the pill represents an improve-
ment over the soft-gel in terms of ease of drug storage and administration. On the other hand,
secondary patents may also be used to extend the time of market exclusivity and to maintain or
even expand the market that the product covers during market exclusivity. These objectives
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can be supported by specific patenting strategies, in particular the creation of patent fences and
clusters. According to [8], “a key element of any life cycle management strategy is to extend
patent protection beyond the basic patent term for as long as possible by filing secondary pat-
ents which are effective to keep generics off the market.”
The scarce available evidence on secondary patents suggests that secondary patents are per-
vasive and that they seem to be used overwhelmingly as a strategic tool. For example, the Euro-
pean Commission found in its 2009 pharmaceutical sector inquiry a primary to secondary
patent ratio of 1:7 [5]. This ratio is higher for pending than granted patents (1:13 vs. 1:5),
which suggests that a large number of secondary patent filings are not granted, presumably be-
cause they do not meet the statutory patentability requirements or because they are not pur-
sued by the applicant, having served their purpose of increasing uncertainty. The inquiry
shows that 57% of secondary patent filings protect formulations, 7% devices, 7% combinations
of known active ingredients, 5% polymorphic forms, 4% salts, and the remaining 20% are ac-
counted by a range of claims, such as hydrates or solvates [5]. The study also reveals that if the
validity of an originator’s patent is challenged either through post-grant opposition or an inval-
idation action in court, the majority of secondary patents is invalidated as a result (or their
claims restricted) [6]. [9] conduct a similar study for the U.S. They look specifically at patenting
associated with 342 new active ingredients approved by the U.S. FDA between 1991 and 2005.
They find that around 50% of drugs are protected by secondary patents. There is an increase in
the share of drugs with secondary patents over time whereas the share of drugs protected by
primary patents remains constant. This filing pattern was also found by [10] who studies the
patenting behavior of companies that market Phosphodiesterase Type 5 inhibitors (for the
treatment of erectile dysfunction). He also finds that the originator companies included in his
study, Pfizer, Bayer and Ely Lilly, file a large amount of secondary patents during later stages of
the life-cycle of a drug. This is suggestive of the fact that secondary patents are filed later in the
life cycle of a drug to extend the patent life. In fact, the data for the U.S. by [9] reveals that com-
pound patents are filed before FDA approval whereas secondary patents are filed mostly after
approval. The authors estimate that secondary patents generate between 4–5 years of additional
patent life on top of compound patents associated with a drug. The mean masks considerable
variation. For example, [7] found for their case study of two HIV drugs that secondary patents
extend patent protection up to 12 years beyond the lifetime of the original primary patents. Al-
though this number might overstate the effective extension of a drug’s patent protection be-
cause [7] include patent applications (as opposed to grants) as well as granted patents not
listed in the Orange Book (which may be a lot less effective in preventing generic entry). An-
other example is Sanofi Aventis’s ARAVA arthritis drug in Australia. Sanofi Aventis effectively
extended exclusivity by 10 years through secondary patents (Sanofi-Aventis Australia Pty Ltd v
Apotex Pty Ltd (No.3) [2011] FCA 346). Other examples of blockbuster drugs are GlaxoS-
mithKline’s antidepressant Paxil or Pfizer’s cholesterol-lowering Lipitor. In both cases, second-
ary patents extend patent protection by several years relative to the original compound patents
[6,11]. It is, therefore, not surprising that the available evidence indicates a positive correlation
between the number of secondary patents for a given drug and higher sales.
An important element in the filing strategy of secondary patents is the creation of legal un-
certainty. For example, in their study of HIV drugs [7] found overlapping patent claims for a
number of formulation patents. They also show that some of the formulation patents protect
variations of known excipients (for example on new flavors such as peppermint or vanilla), or
combinations of known excipients. According to their assessment, these patents are likely in-
valid. [8] report the case of AstraZeneca’s Prilosec. While courts in the U.S. upheld secondary
patents that AstraZeneca had filed to extend the time of patent protection on Prilosec, the Pat-
ents Court in the U.K. invalidated the same formulation patents. This case illustrates that the
Primary and Secondary Pharmaceutical Patents in Chile
PLOS ONE | DOI:10.1371/journal.pone.0124257 April 27, 2015 4 / 17
question of validity of granted secondary patents is particularly unclear. [12] even conclude
from their analysis of patent challenges by generics companies in the U.S. that challenges target
secondary patents and are thus mostly used to restrain attempts by originator companies to ex-
tend patent terms beyond the original active ingredient patents through secondary patents.
Regulatory Framework
Registration of pharmaceutical products
Any drug marketed in Chile has to be registered with the Public Health Institute (ISP) – a gov-
ernment agency (Decree of the Health Ministry No. 1876 from 1995). The same rules apply re-
gardless of whether the drug is imported or locally produced. Registration of new drugs with
the ISP takes on average between 6 and 18 months. Registration fees are moderate (around US
$2,300) and registrations have to be renewed after five years.
If a drug has already been registered on the ISP register, a company that wants to register a
generic version can rely on the studies submitted for the first registration as proof of safety and
efficacy provided the period of data exclusivity has expired. Also, since July 2008 (Resolution
No. 3225/08), the ISP started requiring proof of bioequivalence for products that contain cer-
tain active ingredients. The number of affected active ingredients remained small during the
period that we study (up to 2010), but has increased substantially since 2011 (see http://www.
ispch.cl/medicamentos-bioequivalentes). For these products, the second party to register a
drug has to submit studies of bioequivalence. However, because most drugs are still exempt
from proving bioequivalence, most generics do not necessarily satisfy bioequivalence despite
being pharmaceutically equivalent.
Patent protection is irrelevant for registration at the ISP. In contrast to the U.S. FDA for ex-
ample, in Chile patent information concerning a new drug is neither requested nor verified
when marketing approval is granted.
Apart from patent protection, the regulatory system in Chile also offers additional means
for achieving exclusivity for new drugs. Data related to the safety and efficacy of new chemical
entities provided for approval of new chemical entities is granted five-year exclusivity since
2005 (see also below), in cases where protection is requested by the applicant and granted by
the ISP. This means that generics companies cannot refer to the data when applying for ap-
proval of a drug.
Patents
Pharmaceutical drugs became patentable in Chile in 1991 through Law 19.039. The law offers
patent protection for both products and processes and initially provided a statutory patent life
of 15 years from the date the patent was granted, regardless of subject matter. The law exclud-
ed, however, all patents that had been applied for anywhere else in the world before the law
came into force. Although the law still offered a way to obtain patent protection in Chile even if
a patent had been granted in another jurisdiction before Law 19.039 entered into force (Law
19.039, Article 39), pharmaceutical patents were specifically exempted from this provision
(Law 19.039 Transitional Provisions, Article 1).
Law 19.039 was amended several times during the period that we study (up to 2010): in
2005 by Law 19.996 and in 2007 by Law 20.160 (Law 17.336 in 2010 did not affect the patents
contained in our sample.). The amendments brought Chile’s IP legal framework inline with
TRIPS (taking advantage of the 10-year transition period for developing countries under
TRIPS) and Chile’s obligations under FTAs with the U.S. and the European Free Trade Associ-
ation (EFTA). Apart from a general extension of the patent term from 15 years from the date
the patent was granted to 20 years from the application date, the most relevant changes
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affecting specifically pharmaceutical patents are the introduction of supplementary patent pro-
tection due to delays in the granting of a patent or the sanitary registration (Law 20.160, Article
53), the 5-year data exclusivity for new active ingredients mentioned above (Law 19.996, Article
89), a Bolar exemption (Law 20.160, Article 49), a softening of restrictions on second use pat-
ents (Law 19.996, Article 37e), and international exhaustion of patent rights (Law 19.996, Arti-
cle 49) which effectively legalized parallel imports as long as the products were marketed
abroad by the patent holder (or with the patent holder’s consent).
Finally, Chile joined the PCT system in 2009, which facilitates the international filing of pat-
ents. Although Chile’s accession to the PCT is likely to have had some effect on patent filings
by foreign pharmaceutical companies in Chile, the change occurred in June 2009, which means
it does not affect patent filings observed in our dataset.
Data Description
To construct a dataset that combines patents and trademarks at the product level, we rely on a
dataset that contains the universe of patents and trademarks filed with the Chilean patent office
since 1991. This includes all patent and trademark applications by domestic as well as foreign
entities, regardless of whether or not they have been granted.
To map patents to pharmaceutical products, we use the pharmaceutical registration data
available at the ISP. The institute maintains a database that links all registered drugs in Chile to
the pharmaceutical compounds that they contain. The database also contains additional infor-
mation on the drug (e.g. when it was registered), the owner of the drug, whether the drug is
produced domestically or abroad. We use the bridge between compounds and drugs contained
in ISP’s database to link patents and trademarks at the product-level. Patents are linked to ac-
tive ingredients whereas trademarks are linked to drug names. The link between patents and
drugs represents a challenge as there is usually no explicit mention of the specific compounds
in patent claims. Patents use the IUPAC (International Union of Pure and Applied Chemistry)
classification to identify compounds whereas drugs rely onWHO’s INN (International Non-
proprietary Name). Although compounds are usually described by a Markush structure in the
patent, the same structure comprises often many functionally equivalent active ingredients;
only the combination of specific examples provided in the patent and the Markush structure
reveals the specific active ingredient protected by the patent (for details see the online appendix
available at http://bit.ly/ahh_pharma).
We address this problem in three ways. First, we use a dataset compiled by INAPI that con-
tains the compound-patent mapping for all new compounds registered with the ISP between
2005 and 2010. The mapping was undertaken by patent examiners specialized in pharmaceuti-
cal patents. Second, for all other compounds, we rely on the Orange Book of the U.S. FDA to
identify U.S. patents on the compounds registered in Chile. We then construct patent families
for these U.S. patents and verify whether there are any Chilean equivalents. Similarly, we un-
dertake the same exercise using the Merck Index, which provides information on patents
worldwide. Third, we asked specialists in pharmaceutical patents in Chile to match the remain-
ing set of granted Chilean patents (nearly 3,000 patents) to our list of ISP products directly. As
noted earlier, this leaves a large number of Chilean patent applications that neither matched to
the Orange Book or Merck Index nor were granted that we were unable to search, but we ex-
pect that the matches to drugs in this set of patents will be very small in number.
The mapping between drugs and trademarks is more straightforward as the ISP database
provides the names under which drugs are marketed, which we use to search for these drug
names in our trademark database. In addition to matching drug names, we also match the
names of all companies in the ISP database with the trademark register. Especially in the case
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of generics companies, individual drugs may not be trademarked, but the name of the
company – which presumably appears on the packaging – will be.
The online appendix describes the data construction in more detail and Table 1 gives a sum-
mary of our patent-trademark match to the ISP register. Of 12,116 unique products registered
at the ISP, 3,709 match to at least one Chilean patent, whereas 9,273 match to at least one Chil-
ean trademark. After cleaning and translation of the active ingredients (including some stan-
dardization of names), there are far fewer active ingredients than products, as one might have
expected. Of the 2,630 distinct active ingredients (many of which are common chemical com-
pounds, that is, generics – for example vitamins), 322 match to at least one Chilean patent (504
distinct patents) and 2,332 match at to at least one Chilean trademark (10,461 distinct trade-
marks). Overall 82 per cent of the products and 91 per cent of the active ingredients are associ-
ated with some form of IP protection, more often trademark than patent.
Fig 1 shows the time trends for the unique product-active ingredient combinations. There is
a marked increase in the share using patents during the mid-1990s. Also the share relying only
on trademarks increases substantially beginning the second half of the 1990s.
Table 1. Matching results.
Matched to Shares matched
Total patents trademarks patents trademarks
Unique ISP registrations 14,504 4,304 9,695 29.7% 66.8%
Unique product names 12,116 3,709 9,273 30.6% 76.5%
Unique active ingredients 2,630 322 2,332 12.2% 88.7%
doi:10.1371/journal.pone.0124257.t001
Fig 1. Time-trend patents and trademarks for unique product-active ingredient combination.
doi:10.1371/journal.pone.0124257.g001
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When we examine the ownership of this IP, we see striking differences in the regional pat-
terns. Figs 2 and 3 show the share of patent (Fig 2) and trademark (Fig 3) filings coming from
domestic and foreign entities in Chile, by date of the corresponding ISP registration. Almost all
the patent filings are by entities based in Europe and the U.S., with the exception of a small in-
crease in Chilean-origin filings during the most recent period. The total share of Chilean-origin
filings is less than two per cent of total pharmaceutical patent filings, and none of these filings
match to active ingredients in the ISP registration data. In contrast, over half the trademark fil-
ings are by Chilean entities, with the other half largely from Europe and the U.S. This pattern
points to important differences in terms of the type of drugs marketed by domestic and foreign
entities. Foreign originator companies rely on exclusivity through patent protection (in combi-
nation with trademark protection as shown in Table 2 below) whereas domestic companies
compete (at least to some degree) through brand recognition in the generics market.
Results
Our main interest is in the use of secondary patents by foreign originator companies in Chile.
Collecting the relevant data for investigating this question is challenging. We rely on the identi-
fication of our patents as primary or secondary that was done by internal and external patent
examiners at INAPI following the classification proposed by [9]. Of the 504 Chilean pharma-
ceutical patents that match to our list of active ingredients, 113 (22%) were identified as prima-
ry patents, with the remaining 78% being secondary. This ratio of 1:4 is comparable to the ratio
of 1:5 found for granted patents by the pharmaceutical sector inquiry of the European Com-
mission [5]. If we look at all granted patents regardless of whether they have matched to a
product registered at the ISP, we find that there are more primary than secondary patents. This
could simply be the result of secondary patents facing a higher likelihood of rejection by the
Chilean patent office which would be consistent with the findings of the EU Commission dis-
cussed above. Hence this does not necessarily mean that the ratio of primary to secondary pat-
ents is the same for patent applications (pre-grant).
The 504 matched patents are associated with 322 of the 2,630 active ingredients. Of these ac-
tive ingredients, less than one third (101) have at least one primary patent. In about 88% of the
cases with a primary patent, a primary patent is the first patent on that ingredient; in the re-
maining cases, there is a secondary patent preceding the primary patent.
Figs 4, 5 and 6 examine the patent-active ingredient match more closely. Fig 4 shows the
trends in ISP-matched pharmaceutical patent applications for the two types of patents sepa-
rately for the 1991–2010 period, by date of patent application. During the 1990s after the intro-
duction of pharmaceutical product patents, both types of applications increase but after 2005
there is substantial decline, which may reflect the introduction of data protection and the
worldwide slowdown in the introduction of new pharmaceuticals.
Figs 5 and 6 focus only on the ISP registrations that contain a new active ingredient and use
the date of the ISP registration rather than the date of the patent application. Fig 5 counts
unique patent applications, showing the breakdown between primary and secondary patents
by the date of the first ISP registration containing an active ingredient that has been associated
with the patent. There are 316 such patents; the remaining patents are associated with later ap-
pearances of the same active ingredient, because they are on compounds rather than single
chemicals. Clearly there are almost no primary patents associated with pre-1991 ISP registra-
tions, as one would expect given the absence of pharmaceutical product patentability. There
are a number of secondary patents, however, suggesting that new formulations or uses of older
ISP-registered products were patented after 1991.
Primary and Secondary Pharmaceutical Patents in Chile
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Fig 2. Time-trend patent filings by foreign and domestic entities.
doi:10.1371/journal.pone.0124257.g002
Fig 3. Time-trend trademark filings by foreign and domestic entities.
doi:10.1371/journal.pone.0124257.g003
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Fig 6 also counts only unique ISP registrations the first time an active ingredient appears. It
shows the share of these registrations that are covered by primary, secondary, or both types of
patents during six time periods. This figure also makes it clear that patent coverage of new
drugs is increasing, and that an increasing number of these drugs are covered by primary pat-
ents. Note that there may be some truncation during the 2006–2010 period due to incomplete
patent data (patent applications that follow the ISP registration in the later years will be miss-
ing, implying an undercount of secondary patents, in particular). In spite of the increase in pat-
ent coverage, it is still the case that several hundred active ingredients registered at the ISP for
the first time after the year 2000 are not associated with any Chilean patent applications. Many
but not all of these ingredients are new virus vaccines or new ingredients for over-the-counter
preparations such as vitamin compounds, etc.
To investigate the timing between a Chilean patent application and the first associated ISP
registration further, we computed the lag between the two and plotted the distributions for















# % # % # %
Patent only 3 5% 11 5% 1 3%
Patent and trademark 58 95% 210 95% 39 98%
Total 61 221 40
doi:10.1371/journal.pone.0124257.t002
Fig 4. Pharmaceutical patent applications by type.
doi:10.1371/journal.pone.0124257.g004
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primary and secondary patents in Fig 7. This figure clearly shows that the great majority (86%)
of the primary patents are applied for before the first time the associated ingredient is
Fig 5. Pharmaceutical patent applications by year of first associated ISP registration.
doi:10.1371/journal.pone.0124257.g005
Fig 6. New ISP registrations and patenting.
doi:10.1371/journal.pone.0124257.g006
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registered at the ISP. In contrast, only 56% of the secondary patents are applied for before the
initial ISP registration. A nonparametric test of the difference between the two lag distributions
yields a χ2(1) of 37.5 and is highly significant. The median lag for primary patents is 6 years
and for secondary patents it is 2 years. In a number of cases, the lags are over 5 years, which
suggests delayed entry into the market.
Fig 8 looks at the number of patents that protect a given active ingredient. About 55% of the
active ingredients are protected by a single patent and 34% of active ingredients that are patent
protected are protected by 2 or 3 patents. Very few active ingredients are associated with a larg-
er number of patents. When we look at the breakdown into primary and secondary patents
72% of active ingredients that are protected by a single patent are in fact protected by a second-
ary patent. Among drugs that are protected by several patents, in most cases they are protected
by only secondary patents or a combination of primary and secondary patents.
Table 2 combines the data on trademark protection with the information on primary/sec-
ondary patents. This provides additional insight into the IP strategies of foreign originator
companies. The table shows that nearly all active ingredients that are protected by a patent are
also protected by a trademark. This indicates that companies rely on a patent-trademark com-
bination to achieve market exclusivity. Moreover, there are no significant differences between
active ingredients that are protected by either primary or secondary patents. That said, it ap-
pears that active ingredients protected by a combination of primary and secondary patents are
even more likely to rely on both trademark and patent protection.
To gauge the effect of secondary patents on potential patent term extensions, Fig 9 looks at
the lag between the application date of the first primary patent and that of the latest secondary
patent by active ingredient. The figure shows that in most cases the lag is positive, meaning the
application for the secondary patent was filed after the primary patent, and in many cases this
lag amounts to several years. If the secondary patent offered exclusivity to some degree, Fig 9
Fig 7. Lag between patent application and product registration.
doi:10.1371/journal.pone.0124257.g007
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would suggest that in some cases, companies could gain a number of additional years of patent
exclusivity through the filing of secondary patents. The median number of possible additional
Fig 9. Lag between earliest primary patent and latest secondary patent by active ingredient (active
ingredients protected by both primary and secondary patents).
doi:10.1371/journal.pone.0124257.g009
Fig 8. Combinations of primary and secondary patents.
doi:10.1371/journal.pone.0124257.g008
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years is four, which is consistent with the numbers estimated by [9] for the United States. The
active ingredient with the longest lag (15 years) is Posaconazole, an anti-fungal for which a
crystalline form was patented in the United States 19 years after the original patent (see US pat-
ents 5278175 and 8435998).
Table 3 shows the number of primary and secondary patents associated with each therapeu-
tic class (the total number of entries in the table is 1,246 because there can be more than one
class for a given patent—see also Tables A-7-A-9 in the online appendix). The shares of prima-
ry patents vary considerably: recall that product patents were not available in Chile before
1991. This means that classes like anti-depressants and anti-ulcer (gastrointestinal agents)
which had important patents prior to that date are covered largely by secondary patents. In
contrast, newer areas like anti-virals and anti-neoplastics (anti-cancer) have a large share of
primary patents.
One of way of assessing the importance of secondary patents for extending market exclusivi-
ty is to analyze whether there are any differences in the use of secondary patents by type of pat-
ent owner – in particular distinguishing between for-profit companies and not-for-profit
research institutes and universities. In Fig 10 we distinguish between these two types of assign-
ees. The figure shows that the share of secondary patents among patent-protected active ingre-
dients is significantly larger for companies than for universities/not-for-profit research
institutes. There are only 5 secondary patents that are assigned to universities and not-for-prof-
it research institutes. However, with the exception of one secondary patent which is assigned to
the Wellcome Foundation, all other secondary patents are co-assigned to universities/not-for-
Table 3. Number of patents per therapeutic class.
Number Share
Therapeutic group Primary patents Secondary patents Primary patents
anti-viral agents 20 41 32.8%
anti-neoplastics 14 23 37.8%
anti-depressants 2 33 5.7%
anti-psychotics 1 31 3.1%
anti-diabetic agents 8 24 25.0%
analgesics 8 23 25.8%
nonsteroidal anti-inflammatory agents 7 20 25.9%
immunologic agents 9 13 40.9%
antibiotics/anti-neoplastics 5 17 22.7%
gastrointestinal agents (anti-ulcer) 2 19 9.5%
anti-fungals 3 16 15.8%
broncho-dilators 1 18 5.3%
anti-asthmatic combinations 3 15 16.7%
anti-histamines 2 15 11.8%
agents for pulmonary hypertension 1 15 6.3%
bone resorption inhibitors 0 16 0.0%
quinolones 3 12 20.0%
cholesterol absorption inhibitors 3 11 21.4%
hormones 1 11 8.3%
narcotic analgesics 2 10 16.7%
anti-infectives 2 10 16.7%
remaining classes 63 421 13.0%
Total 160 814
doi:10.1371/journal.pone.0124257.t003
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profit research institutes and private companies. This suggests that secondary patents are al-
most exclusively used by private companies as a tool to achieve exclusivity. That said, universi-
ties tend to focus on early stage research which is less likely to lead to the filing of secondary
patents. Taking a closer look at patenting companies, we find that 76 out of 123 companies
(62%) only file secondary patents whereas 25 companies (20%) only file primary patents (22
companies file both types of patents).
Conclusion
Our objective was to take a first look at patenting of pharmaceuticals in Chile, with a particular
focus on the distinction between primary and secondary patents. We provide a number of de-
scriptive findings that show that pharmaceutical patents associated with drugs that have re-
ceived market approval are almost exclusively the domain of foreign originator companies.
Overall, we find that only a subset of drugs with market approval is protected by patents, a
much larger number of products are protected by trademarks. We also find that foreign origi-
nator companies rely on a patent-trademark combination whereas domestic companies rely
only on trademarks. Nevertheless, we also find a substantial number of ISP registrations that
are not protected either by a patent or a trademark. When we take a closer look at ISP registra-
tions protected by patents, we find that the majority are protected only by secondary patents
(few active ingredients are protected by more than 1–3 patents). This is especially true before
the change to the patent law in 1991, although it takes a few years for the number of primary
patents to become significant. We also find that nearly all primary patents on active ingredients
were filed before a drug containing the active ingredient was registered with the ISP. Secondary
patents in contrast often follow with a lag of several years, that is, secondary patents are often
filed after primary patents and after a drug has been registered at the ISP. The timing is also re-
flected in the fact that secondary patents dominate “older” therapeutic classes like anti-ulcer
Fig 10. Share of primary/secondary patents by patent owner type.
doi:10.1371/journal.pone.0124257.g010
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and anti-depressants. In contrast, newer areas like anti-virals and anti-neoplastics (anti-cancer)
have a much larger share of primary patents. Our data also reveal that secondary patents are al-
most exclusively a tool used by private companies whereas universities and not-for-profit re-
search institutes concentrate on primary patent protection.
This study is only a first step towards a better understanding of pharmaceutical patents in
Chile. We have assembled a dataset that combines pharmaceutical products, active ingredients,
patents, trademarks, and information on the corresponding companies. These data enable us
to substantially deepen our understanding of the impact of patents on the pharmaceutical in-
dustry in Chile. Still, our approach and data have a number of obvious limitations. Perhaps
most importantly, we only observe whether a drug has obtained market approval, but we have
no information on actual demand or prices. This limits our ability to account for the impor-
tance of different drugs other than through their therapeutic classes.
We plan to extend this work to assess the impact that the combined use of primary and sec-
ondary patents has had on the ability of Chilean companies to compete in the generics indus-
try. Such analysis could produce relevant insights for the current debate on secondary patents.
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